Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03404310 · ClinicalTrials.gov registry record · NA
Zinc Sulfate for Human Papillomavirus (HPV)
A NA study, sponsored by Corewell Health West.
- Terminated
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT03404310: Clinical Trial NA study, sponsored by Corewell Health West.
NCT03404310 is a NA study that was terminated before completion, run by Corewell Health West. The registered enrollment target is 21 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03404310, a NA study, was terminated before completion, sponsored by Corewell Health West.
- TERMINATED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
The Human Papillomavirus (HPV) is well established as the primary causative agent in both warts and cervical cancer. Although cervical high risk HPV (hrHPV) infections have a high rate of spontaneous resolution this takes time and the infection can cause cervical cells to progress to precancerous and cancerous lesions. Zinc has been shown to play a central role in immunity. This study is to determine if oral zinc sulfate can improve clearance rates of high risk HPV versus placebo.
Interventions
- DIETARY_SUPPLEMENT Zinc Sulfate
- OTHER Placebo (Gelatin Tablet)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-10-24 |
| Est. Completion | 2019-06-28 |
| Phase | NA |
Why NCT03404310 stopped before completion
NCT03404310 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Zinc Sulfate is the first listed.
NCT03404310 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03404310 about?
NCT03404310 is a clinical study titled "Zinc Sulfate for Human Papillomavirus (HPV)". The Human Papillomavirus (HPV) is well established as the primary causative agent in both warts and cervical cancer. Although cervical high risk HPV (hrHPV) infections have a high rate of spontaneous resolution this takes time and the infection can cause cervical cells to progress to precancerous an...
What is the current status of trial NCT03404310?
This trial is currently terminated. It is a NA study. The enrollment target is 21 participants. The study started on 2017-10-24. Estimated completion is 2019-06-28.
What interventions are being tested in trial NCT03404310?
The interventions under investigation include: Zinc Sulfate (DIETARY_SUPPLEMENT), Placebo (Gelatin Tablet) (OTHER).
Who is sponsoring clinical trial NCT03404310?
This trial is sponsored by Corewell Health West, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03404310's enrollment target sits among peer trials
21 1762nd of 2000 higher than 233 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI